Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak

Kotak has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Biocon to report net profit at Rs. 176.2 crore up 35.2% year-on-year (down 18.9% quarter-on-quarter).

Net Sales are expected to increase by 31.6 percent Y-o-Y (down 0.1 percent Q-o-Q) to Rs. 1,538.7 crore, according to Kotak.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 60.2 percent Y-o-Y (down 2 percent Q-o-Q) to Rs. 373.2 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.